Abimbola Adegoke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abimbola Adegoke has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kola Adegoke
School of Health Sciences and Practice, New York Medical College, 40 Sunshine Cottage Road, Valhalla, NY 10595, USA, USA
15 shared publications - Deborah Dawodu
McWilliams School of Biomedical Informatics, UTHealth Houston. 7000 Fannin Street, Houston, Texas 77030, USA., USA
10 shared publications - Akorede Adekoya
Department of Virtual Health, Fraser Health, Surrey, British Columbia, Canada
9 shared publications - Temitope Kayode
School of Health Sciences and Practice, New York Medical College, 40 Sunshine Cottage Road, Valhalla, New York, USA
7 shared publications - Adeyinka Adegoke
Department of Business Administration, Northern Alberta Institute of Technology, Edmonton, Alberta, Canada, Canada
5 shared publications - Ayoola Bayowa
Thompson Rivers University, Kamloops, British Columbia, Canada, Canada
4 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Preprints.org
Health Care Access and Cervical Cancer Screening Among American Indian and Alaska Native Women in the United States: An Analysis of the 2022 and 2024 Behavioral Risk Factor Surveillance System(BRFSS)
Introduction/Objectives. We examined associations of personal-provider availability, cost barriers, and primary coverage source with cervical cancer screening among non-Hispanic American Indian and Alaska Native women. Methods. This repeated cross-sectional study used the 2022 and 2024 Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System (BRFSS). Eligible women were aged 21–65 years, reported no hysterectomy, and lived in 49 states or the District of Columbia. Survey-weighted logistic regression included three access measures jointly. Marginal standardization estimated adjusted probabilities. Sensitivity analyses used state adjustment, separate years, and modified Poisson regression. Results. Among 3,755 eligible women, 2,894 had complete data. Having a personal provider was associated with higher screening odds (adjusted odds ratio, 2.41; 95% CI, 1.50–3.86). Adjusted probabilities were 36.0% without and 55.8% with a provider, a 19.8-percentage-point difference (95% CI, 9.5–30.0). The adjusted prevalence ratio was 1.56 (95% CI, 1.20–2.03). Cost and coverage estimates were imprecise and included the null. Conclusions. Provider availability was consistently associated with screening across models. Findings support evaluating provider-linkage strategies, but cross-sectional measurement, questionnaire changes, and complete-case selection limit causal and temporal interpretation.
- 18 November 2026
- Published by MDPI AG in Preprints.org
Open AccessHealth Care Access and Cervical Cancer Screening Among American Indian and Alaska Native Women in the United States: An Analysis of the 2022 and 2024 Behavioral Risk Factor Surveillance System(BRFSS)
Introduction/Objectives. We examined associations of personal-provider availability, cost barriers, and primary coverage source with cervical cancer screening among non-Hispanic American Indian and Alaska Native women. Methods. This repeated cross-sectional study used the 2022 and 2024 Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System (BRFSS). Eligible women were aged 21–65 years, reported no hysterectomy, and lived in 49 states or the District of Columbia. Survey-weighted logistic regression included three access measures jointly. Marginal standardization estimated adjusted probabilities. Sensitivity analyses used state adjustment, separate years, and modified Poisson regression. Results. Among 3,755 eligible women, 2,894 had complete data. Having a personal provider was associated with higher screening odds (adjusted odds ratio, 2.41; 95% CI, 1.50–3.86). Adjusted probabilities were 36.0% without and 55.8% with a provider, a 19.8-percentage-point difference (95% CI, 9.5–30.0). The adjusted prevalence ratio was 1.56 (95% CI, 1.20–2.03). Cost and coverage estimates were imprecise and included the null. Conclusions. Provider availability was consistently associated with screening across models. Findings support evaluating provider-linkage strategies, but cross-sectional measurement, questionnaire changes, and complete-case selection limit causal and temporal interpretation.
- Open Access
- 19 May 2026
- Published by SAGE Publications in Health Services Insights
- Vol. 19
Most-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom
Background: Soaring drug prices pose a significant obstacle to affordable and equitable access to medicines in high-income healthcare systems. This study compares two leading reform tool families, Most Favored Nation (MFN)/international reference pricing (IRP) and value-based contracting (VBC), across the United States, Canada, and the United Kingdom, with attention to cost containment, value-linked incentive design, equity of access, and implementation feasibility. U.S. policy developments (CMS Innovation Center’s GENEROUS, GLOBE, and GUARD models) extend international benchmark-based design options beyond the 2020 MFN rule. Methods: Guided by institutional and governance theories, we conducted a structured comparative policy analysis using a four-dimensional trade-off matrix. Cases from the United States, Canada, and the United Kingdom were selected using a most-different-systems design. Documents from 2007 to 2025 were coded for cost containment, value-linked incentive design, equity, and implementation feasibility. To reduce subjectivity, scores were assigned using prespecified rubric anchors, conservative scoring rules for borderline cases, and a sensitivity check of adjacent-score judgments. Design-stage U.S. benchmark-based model materials assessed on March 5, 2026, were incorporated descriptively and not considered as outcome evidence. Results: The United Kingdom model, centered on the National Institute for Health and Care Excellence (UK NICE) and the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), was most consistently aligned across all four dimensions (design-feature alignment). Canada’s Patented Medicine Prices Review Board (PMPRB) supports affordability and baseline access, with implementation variation across provinces and more limited adoption of outcomes-based contracting. U.S. MFN/IRP initiatives and VBC pilots show lower alignment on equity and feasibility in a multi-payer environment characterized by contested authority and variable data/contracting capacity. Emerging CMS Innovation Center proposals (GENEROUS, GLOBE, GUARD) indicate continued federal interest in benchmark-based designs, but empirical impacts remain to be evaluated. Conclusions: MFN/IRP anchoring and VBC are implementation-intensive tools whose performance depends on institutional fit. A hybrid approach, using international benchmarks as inputs for negotiations and expanding value-linked agreements where measurement and governance prerequisites are met, may offer a more feasible U.S. pathway. This study provides a repeatable framework for assessing drug pricing reforms and illustrates how institutional alignment conditions the implementability of tools. Design-feature scores reflect policy design and governance capacity, not realized outcomes.
- 19 May 2026
- Published by SAGE Publications in Health Services Insights
- Vol. 19
Open AccessMost-Favored-Nation Benchmarking Versus Value-Based Contracting: Institutional Fit of Pharmaceutical Pricing Tools in the United States, Canada, and the United Kingdom
Background: Soaring drug prices pose a significant obstacle to affordable and equitable access to medicines in high-income healthcare systems. This study compares two leading reform tool families, Most Favored Nation (MFN)/international reference pricing (IRP) and value-based contracting (VBC), across the United States, Canada, and the United Kingdom, with attention to cost containment, value-linked incentive design, equity of access, and implementation feasibility. U.S. policy developments (CMS Innovation Center’s GENEROUS, GLOBE, and GUARD models) extend international benchmark-based design options beyond the 2020 MFN rule. Methods: Guided by institutional and governance theories, we conducted a structured comparative policy analysis using a four-dimensional trade-off matrix. Cases from the United States, Canada, and the United Kingdom were selected using a most-different-systems design. Documents from 2007 to 2025 were coded for cost containment, value-linked incentive design, equity, and implementation feasibility. To reduce subjectivity, scores were assigned using prespecified rubric anchors, conservative scoring rules for borderline cases, and a sensitivity check of adjacent-score judgments. Design-stage U.S. benchmark-based model materials assessed on March 5, 2026, were incorporated descriptively and not considered as outcome evidence. Results: The United Kingdom model, centered on the National Institute for Health and Care Excellence (UK NICE) and the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), was most consistently aligned across all four dimensions (design-feature alignment). Canada’s Patented Medicine Prices Review Board (PMPRB) supports affordability and baseline access, with implementation variation across provinces and more limited adoption of outcomes-based contracting. U.S. MFN/IRP initiatives and VBC pilots show lower alignment on equity and feasibility in a multi-payer environment characterized by contested authority and variable data/contracting capacity. Emerging CMS Innovation Center proposals (GENEROUS, GLOBE, GUARD) indicate continued federal interest in benchmark-based designs, but empirical impacts remain to be evaluated. Conclusions: MFN/IRP anchoring and VBC are implementation-intensive tools whose performance depends on institutional fit. A hybrid approach, using international benchmarks as inputs for negotiations and expanding value-linked agreements where measurement and governance prerequisites are met, may offer a more feasible U.S. pathway. This study provides a repeatable framework for assessing drug pricing reforms and illustrates how institutional alignment conditions the implementability of tools. Design-feature scores reflect policy design and governance capacity, not realized outcomes.
- Open Access
- 2 May 2026
- Published by MDPI AG in Preprints.org
Improving Continuity of Care in High-Income Countries by Obtaining External Clinical Notes Before Scheduled Primary Care Visits: A Scoping Review of Workflow, Value, and Evidence Gaps
This scoping review examined how external clinical notes are obtained and used before scheduled primary care visits in high-income countries, with attention to continuity of care, workflow integration, value, healthcare delivery, policy, and risk. Within the health data ecosystem, the value of external clinical data depends not only on exchange capability but also on whether information is timely, easy to find, and usable in practice. Guided by Arksey and O’Malley, Joanna Briggs Institute guidance, and PRISMA-ScR, the review searched PubMed, CINAHL, and Google Scholar for English-language, peer-reviewed studies published from 2021 to 2026. Of 330 records identified, 15 studies were included and assigned Johns Hopkins evidence levels and quality ratings. The evidence base was dominated by Level III studies, indicating stronger support for conclusions about workflow barriers, usability, and care coordination than for causal or economic effects. Three patterns emerged: technical exchange alone did not ensure continuity of care, workflow integration shaped whether external information was useful, and the literature described clinical and operational value more clearly than direct financial return. Using the Sittig and Singh sociotechnical model, the review shows that value is produced or lost across infrastructure, clinical content, interface design, people, workflow, organizational conditions, external rules, and monitoring. Overall, external clinical notes function as high-value data only when they are available before the visit, routed appropriately, and usable within the routine primary care workflow. Future research should use stronger workflow-specific measures and assess cost implications and return on investment more consistently.
- 2 May 2026
- Published by MDPI AG in Preprints.org
Open AccessImproving Continuity of Care in High-Income Countries by Obtaining External Clinical Notes Before Scheduled Primary Care Visits: A Scoping Review of Workflow, Value, and Evidence Gaps
This scoping review examined how external clinical notes are obtained and used before scheduled primary care visits in high-income countries, with attention to continuity of care, workflow integration, value, healthcare delivery, policy, and risk. Within the health data ecosystem, the value of external clinical data depends not only on exchange capability but also on whether information is timely, easy to find, and usable in practice. Guided by Arksey and O’Malley, Joanna Briggs Institute guidance, and PRISMA-ScR, the review searched PubMed, CINAHL, and Google Scholar for English-language, peer-reviewed studies published from 2021 to 2026. Of 330 records identified, 15 studies were included and assigned Johns Hopkins evidence levels and quality ratings. The evidence base was dominated by Level III studies, indicating stronger support for conclusions about workflow barriers, usability, and care coordination than for causal or economic effects. Three patterns emerged: technical exchange alone did not ensure continuity of care, workflow integration shaped whether external information was useful, and the literature described clinical and operational value more clearly than direct financial return. Using the Sittig and Singh sociotechnical model, the review shows that value is produced or lost across infrastructure, clinical content, interface design, people, workflow, organizational conditions, external rules, and monitoring. Overall, external clinical notes function as high-value data only when they are available before the visit, routed appropriately, and usable within the routine primary care workflow. Future research should use stronger workflow-specific measures and assess cost implications and return on investment more consistently.
- Open Access
- 25 March 2026
- Published by Public Library of Science (PLoS) in PLOS Mental Health
- Vol. 3 (3) , e0000307
From crisis to recovery: Exploring the demand surge for mental health services in Alberta, Canada—A document-based policy analysis with an illustrative supply–demand simulation (2023–2024)
COVID-19 coincided with increased mental health needs in Alberta, Canada, intensifying pre-existing access gaps and service strain. Alberta responded with publicly funded interventions spanning digital care, youth-focused services, and recovery-oriented programs. To evaluate Alberta’s system-level response to pandemic-related increases in mental health help-seeking/service uptake using a health economics and policy lens. We extracted empirically reported program delivery outputs from the 2023–2024 Alberta Mental Health and Addiction Annual Report. We used a simulation calibrated to reported trends to examine directional changes in help-seeking (demand), service capacity (supply), and the modeled equilibrium quantity under a zero-copayment design. Empirically reported outputs indicate that delivery met or exceeded planned/funded milestones for CASA Mental Health, VODP, and tele-mental health, while recovery communities reflected phased implementation. In the illustrative simulation, the demand-implied volume increases from 60 to 87 services/month, but delivered volume is capacity-constrained at 78 services/month (implying ~9 services/month unmet demand), while a unit-cost proxy is held constant for visualization (not an observed market price or patient copayment). Alberta’s response illustrates how coordinated, publicly funded capacity expansion and access-oriented policies can support service delivery during system shocks; the model also highlights that if capacity growth lags demand growth, unmet need may persist even under zero copayment.
- 25 March 2026
- Published by Public Library of Science (PLoS) in PLOS Mental Health
- Vol. 3 (3) , e0000307
Open AccessFrom crisis to recovery: Exploring the demand surge for mental health services in Alberta, Canada—A document-based policy analysis with an illustrative supply–demand simulation (2023–2024)
COVID-19 coincided with increased mental health needs in Alberta, Canada, intensifying pre-existing access gaps and service strain. Alberta responded with publicly funded interventions spanning digital care, youth-focused services, and recovery-oriented programs. To evaluate Alberta’s system-level response to pandemic-related increases in mental health help-seeking/service uptake using a health economics and policy lens. We extracted empirically reported program delivery outputs from the 2023–2024 Alberta Mental Health and Addiction Annual Report. We used a simulation calibrated to reported trends to examine directional changes in help-seeking (demand), service capacity (supply), and the modeled equilibrium quantity under a zero-copayment design. Empirically reported outputs indicate that delivery met or exceeded planned/funded milestones for CASA Mental Health, VODP, and tele-mental health, while recovery communities reflected phased implementation. In the illustrative simulation, the demand-implied volume increases from 60 to 87 services/month, but delivered volume is capacity-constrained at 78 services/month (implying ~9 services/month unmet demand), while a unit-cost proxy is held constant for visualization (not an observed market price or patient copayment). Alberta’s response illustrates how coordinated, publicly funded capacity expansion and access-oriented policies can support service delivery during system shocks; the model also highlights that if capacity growth lags demand growth, unmet need may persist even under zero copayment.
- Open Access
- 1 March 2026
- Published by SAGE Publications in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
- Vol. 63
Medicaid Expansion and Frequent Mental Distress Among U.S. Adults: Staggered DiD Using BRFSS, 2011 to 2024
The Affordable Care Act (ACA) allowed states to expand Medicaid eligibility, potentially improving access to care and reducing psychological distress among lower-income adults. However, evidence on population-level mental health effects remains mixed, and conventional two-way fixed-effects difference-in-differences (DiD) estimates can be biased under staggered adoption. This study estimates the effect of Medicaid expansion on frequent mental distress (FMD) among non-elderly adults, with emphasis on lower-income adults. We used Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 to 2024 and restricted the sample to adults aged 18 to 64 years. FMD was defined as ≥14 days of poor mental health in the past 30 days. Medicaid expansion was assigned by state implementation year. For transparent weighting and computational feasibility, we collapsed microdata to state-year prevalence using BRFSS survey weights and applied prespecified minimum cell-size and effective-sample screens (lower-income panel: unweighted N ≥ 150 and Kish n_eff ≥ 50; pooled and higher-income panels: n_eff ≥ 200). We estimated group-time average treatment effects using the Callaway–Sant’Anna staggered DiD framework (csdid), clustered standard errors at the state level, and used pair-balanced observations when panels were unbalanced. Income strata were defined using BRFSS household income categories (lower-income: inc_cat = 1; higher-income: inc_cat ∈ {7,8}) and are interpreted as economic-status proxies rather than Medicaid eligibility. In the lower-income state-year panel (353 state-years), Medicaid expansion was not associated with a statistically significant change in FMD (ATT −0.0125; 95% CI −0.0521 to 0.0271; P = .54). Estimates in the higher-income (656 state-years) and pooled (709 state-years) panels were similarly small and not statistically significant. Event-time estimates indicated modest heterogeneity at selected leads/lags without a consistent post-expansion pattern. Medicaid expansion was not associated with significant reductions in population-level frequent mental distress during 2011 to 2024. Any mental health effects appear modest and heterogeneous across cohorts and follow-up periods, suggesting that insurance expansion alone may be insufficient to shift population psychological distress without complementary behavioral health capacity and upstream social supports.
- 1 March 2026
- Published by SAGE Publications in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
- Vol. 63
Open AccessMedicaid Expansion and Frequent Mental Distress Among U.S. Adults: Staggered DiD Using BRFSS, 2011 to 2024
The Affordable Care Act (ACA) allowed states to expand Medicaid eligibility, potentially improving access to care and reducing psychological distress among lower-income adults. However, evidence on population-level mental health effects remains mixed, and conventional two-way fixed-effects difference-in-differences (DiD) estimates can be biased under staggered adoption. This study estimates the effect of Medicaid expansion on frequent mental distress (FMD) among non-elderly adults, with emphasis on lower-income adults. We used Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 to 2024 and restricted the sample to adults aged 18 to 64 years. FMD was defined as ≥14 days of poor mental health in the past 30 days. Medicaid expansion was assigned by state implementation year. For transparent weighting and computational feasibility, we collapsed microdata to state-year prevalence using BRFSS survey weights and applied prespecified minimum cell-size and effective-sample screens (lower-income panel: unweighted N ≥ 150 and Kish n_eff ≥ 50; pooled and higher-income panels: n_eff ≥ 200). We estimated group-time average treatment effects using the Callaway–Sant’Anna staggered DiD framework (csdid), clustered standard errors at the state level, and used pair-balanced observations when panels were unbalanced. Income strata were defined using BRFSS household income categories (lower-income: inc_cat = 1; higher-income: inc_cat ∈ {7,8}) and are interpreted as economic-status proxies rather than Medicaid eligibility. In the lower-income state-year panel (353 state-years), Medicaid expansion was not associated with a statistically significant change in FMD (ATT −0.0125; 95% CI −0.0521 to 0.0271; P = .54). Estimates in the higher-income (656 state-years) and pooled (709 state-years) panels were similarly small and not statistically significant. Event-time estimates indicated modest heterogeneity at selected leads/lags without a consistent post-expansion pattern. Medicaid expansion was not associated with significant reductions in population-level frequent mental distress during 2011 to 2024. Any mental health effects appear modest and heterogeneous across cohorts and follow-up periods, suggesting that insurance expansion alone may be insufficient to shift population psychological distress without complementary behavioral health capacity and upstream social supports.
- Open Access
- 26 January 2026
- Published by MDPI AG in Preprints.org
Health Information Technology Capital Intensity and Hospital Financial Performance: Evidence from U.S. Hospitals, 2018–2023
Background: U.S. hospitals continue to invest in digital infrastructure, yet evidence on how health information technology (HIT) capital investment relates to financial performance, particularly after COVID-19, remains mixed.Objective: To estimate associations between HIT capital intensity and hospital profitability from 2018 to 2023, assess nonlinearity, and test whether associations differed during the COVID-19 years. Methods: Using the RAND HCRIS hospital panel (3,480 hospital-year observations from HIT-reporting hospitals, 2018–2023), we defined HIT capital intensity as HIT-designated capital stock divided by total assets. Primary analyses estimated year-specific regressions with HIT-intensity quintiles and spline specifications for nonlinearity, adjusting for hospital size (log total assets) and teaching status. Pooled models incorporated year fixed effects and HIT-intensity interactions with a COVID indicator (2020–2021). Sensitivity analyses included alternative winsorization (5th/95th percentile), hospital-fixed effects, and placebo tests using non-HIT fixed-asset intensity.Results: Reporter rates ranged from 24.6% (2018; 545/2,212) to 19.4% (2023; 982/5,063). In year-specific quintile models, the highest HIT-intensity quintile (Q5) was associated with lower winsorized total margin versus Q1 in 2018 (β = −0.055; p = 0.008), 2019 (β = −0.042; p = 0.016), and 2023 (β = −0.034; p = 0.010), with weaker estimates in 2020–2022. In pooled interaction models, higher-intensity hospitals exhibited a lower margin gap outside COVID years (e.g., Q5: β = −0.041; p < 0.001) with partial attenuation during COVID (Q5×COVID: β = 0.032; p = 0.073). Hospital fixed-effects estimates for quintiles were not statistically significant (Q5: β = −0.015; p = 0.438). A pooled 5/95 winsorization robustness check remained negative for Q5 (β = −0.029; p < 0.001). Placebo analyses showed similar patterns for non-HIT fixed assets (Q5: β = −0.032; p = 0.006). Conclusions: Higher HIT capital intensity is associated with lower profitability at the upper end of the intensity distribution in some years, with suggestive attenuation during COVID-19. However, the fixed-effects and placebo results are consistent with time-invariant confounding or broader capital-intensity dynamics rather than HIT-specific causal effects. Policies targeting financially constrained hospitals may help sustain digital investment while protecting financial stability.
- 26 January 2026
- Published by MDPI AG in Preprints.org
Open AccessHealth Information Technology Capital Intensity and Hospital Financial Performance: Evidence from U.S. Hospitals, 2018–2023
Background: U.S. hospitals continue to invest in digital infrastructure, yet evidence on how health information technology (HIT) capital investment relates to financial performance, particularly after COVID-19, remains mixed.Objective: To estimate associations between HIT capital intensity and hospital profitability from 2018 to 2023, assess nonlinearity, and test whether associations differed during the COVID-19 years. Methods: Using the RAND HCRIS hospital panel (3,480 hospital-year observations from HIT-reporting hospitals, 2018–2023), we defined HIT capital intensity as HIT-designated capital stock divided by total assets. Primary analyses estimated year-specific regressions with HIT-intensity quintiles and spline specifications for nonlinearity, adjusting for hospital size (log total assets) and teaching status. Pooled models incorporated year fixed effects and HIT-intensity interactions with a COVID indicator (2020–2021). Sensitivity analyses included alternative winsorization (5th/95th percentile), hospital-fixed effects, and placebo tests using non-HIT fixed-asset intensity.Results: Reporter rates ranged from 24.6% (2018; 545/2,212) to 19.4% (2023; 982/5,063). In year-specific quintile models, the highest HIT-intensity quintile (Q5) was associated with lower winsorized total margin versus Q1 in 2018 (β = −0.055; p = 0.008), 2019 (β = −0.042; p = 0.016), and 2023 (β = −0.034; p = 0.010), with weaker estimates in 2020–2022. In pooled interaction models, higher-intensity hospitals exhibited a lower margin gap outside COVID years (e.g., Q5: β = −0.041; p < 0.001) with partial attenuation during COVID (Q5×COVID: β = 0.032; p = 0.073). Hospital fixed-effects estimates for quintiles were not statistically significant (Q5: β = −0.015; p = 0.438). A pooled 5/95 winsorization robustness check remained negative for Q5 (β = −0.029; p < 0.001). Placebo analyses showed similar patterns for non-HIT fixed assets (Q5: β = −0.032; p = 0.006). Conclusions: Higher HIT capital intensity is associated with lower profitability at the upper end of the intensity distribution in some years, with suggestive attenuation during COVID-19. However, the fixed-effects and placebo results are consistent with time-invariant confounding or broader capital-intensity dynamics rather than HIT-specific causal effects. Policies targeting financially constrained hospitals may help sustain digital investment while protecting financial stability.
- Open Access
- 23 January 2026
- Published by MDPI AG in Preprints.org
Financial Margin Dynamics After Hospital Chain-Joining: A Staggered DiD Event Study, 2014–2023
Background: U.S. hospitals have increasingly affiliated with multi-hospital chains, raising questions about whether consolidation yields operational efficiencies or primarily reflects integration costs and market power. Evidence on the dynamic financial response to chain entry—especially in recent years—remains limited.Objective: To estimate dynamic association in hospital financial margins around sustained chain joining using a staggered-adoption-robust event-study design.Methods: We analyzed a RAND-processed HCRIS hospital panel (2014–2023). Dynamic effects were estimated using the Sun & Abraham interaction-weighted event-study estimator with hospital and year fixed effects and hospital-clustered standard errors. We implemented two baseline rules (“has2014” and “entry”) and examined total, operating, and cash-flow margins. To reduce ratio outliers, margins were cleaned using year-specific denominator screening and hard caps for extreme values (|margin|>500%), then winsorized within year (p1/p99) for main analyses. Depending on outcome and baseline rule, models used approximately 13,000–24,000 hospital-year observations, covering ~2,600–2,900 hospitals and roughly 600 sustained chain joins. Robustness checks included a balanced-panel restriction, a treated-only stacked specification, placebo assignment among never-treated hospitals, and ownership-stratified estimates.Results: Lead coefficients were generally small, but cash-flow margins exhibited a statistically detectable negative lead at t = −4 in both baseline rules (p≈0.03), while other leads were typically indistinguishable from zero. Post-entry effects were modest and imprecise across outcomes. Total margins showed near-zero contemporaneous changes at t=0 and small negative estimates in years 1–3 that attenuated by year 4. Operating and cash-flow margins displayed small post-entry declines around t=2 (≈1 percentage point in magnitude; p≈0.06–0.09). Robustness checks (balanced panel, stacked design, placebo) broadly supported a null or weak-transient pattern. Ownership stratification suggested modest longer-run improvements for nonprofit hospitals in later post years (e.g., t=4: +3.7 percentage points; p=0.045), while for-profit estimates were mixed and imprecise.Conclusions: Over 2014–2023, sustained chain joining was not associated with consistent, sustained improvements in hospital financial margins on average. Observed changes were small, often imprecise, and in some outcomes suggest modest short-run declines consistent with integration costs. Continued monitoring with longer post-entry windows and additional outcomes is warranted.
- 23 January 2026
- Published by MDPI AG in Preprints.org
Open AccessFinancial Margin Dynamics After Hospital Chain-Joining: A Staggered DiD Event Study, 2014–2023
Background: U.S. hospitals have increasingly affiliated with multi-hospital chains, raising questions about whether consolidation yields operational efficiencies or primarily reflects integration costs and market power. Evidence on the dynamic financial response to chain entry—especially in recent years—remains limited.Objective: To estimate dynamic association in hospital financial margins around sustained chain joining using a staggered-adoption-robust event-study design.Methods: We analyzed a RAND-processed HCRIS hospital panel (2014–2023). Dynamic effects were estimated using the Sun & Abraham interaction-weighted event-study estimator with hospital and year fixed effects and hospital-clustered standard errors. We implemented two baseline rules (“has2014” and “entry”) and examined total, operating, and cash-flow margins. To reduce ratio outliers, margins were cleaned using year-specific denominator screening and hard caps for extreme values (|margin|>500%), then winsorized within year (p1/p99) for main analyses. Depending on outcome and baseline rule, models used approximately 13,000–24,000 hospital-year observations, covering ~2,600–2,900 hospitals and roughly 600 sustained chain joins. Robustness checks included a balanced-panel restriction, a treated-only stacked specification, placebo assignment among never-treated hospitals, and ownership-stratified estimates.Results: Lead coefficients were generally small, but cash-flow margins exhibited a statistically detectable negative lead at t = −4 in both baseline rules (p≈0.03), while other leads were typically indistinguishable from zero. Post-entry effects were modest and imprecise across outcomes. Total margins showed near-zero contemporaneous changes at t=0 and small negative estimates in years 1–3 that attenuated by year 4. Operating and cash-flow margins displayed small post-entry declines around t=2 (≈1 percentage point in magnitude; p≈0.06–0.09). Robustness checks (balanced panel, stacked design, placebo) broadly supported a null or weak-transient pattern. Ownership stratification suggested modest longer-run improvements for nonprofit hospitals in later post years (e.g., t=4: +3.7 percentage points; p=0.045), while for-profit estimates were mixed and imprecise.Conclusions: Over 2014–2023, sustained chain joining was not associated with consistent, sustained improvements in hospital financial margins on average. Observed changes were small, often imprecise, and in some outcomes suggest modest short-run declines consistent with integration costs. Continued monitoring with longer post-entry windows and additional outcomes is warranted.
- Open Access
- 5 January 2026
- Published by MDPI AG in Preprints.org
From Crisis to Recovery: Mental Health Service Demand in Alberta, Canada — A Policy Analysis with Illustrative Supply–Demand Modeling (2023–2024)
Background: COVID-19 coincided with increased mental health needs in Alberta, Canada, intensifying pre-existing access gaps and service strain. Alberta responded with publicly funded interventions spanning digital care, youth-focused services, and recovery-oriented programs. Objective: To evaluate Alberta’s system-level response to pandemic-related increases in mental health help-seeking/service uptake using a health economics and policy lens. Methods: We extracted empirically reported program delivery outputs from the 2023–2024 Alberta Mental Health and Addiction Annual Report. We used a simulation calibrated to reported trends to examine directional changes in help-seeking (demand), service capacity (supply), and the modeled equilibrium quantity under a zero-copayment design. Results: Empirically reported outputs indicate that delivery met or exceeded planned/funded milestones for CASA Mental Health, VODP, and tele-mental health, while recovery communities reflected phased implementation. In the illustrative simulation, the demand-implied volume increases from 60 to 87 services/month, but delivered volume is capacity-constrained at 78 services/month (implying ~9 services/month unmet demand), while a unit-cost proxy is held constant for visualization (not an observed market price or patient copayment).Conclusion: Alberta’s response illustrates how coordinated, publicly funded capacity expansion and access-oriented policies can support service delivery during system shocks; the model also highlights that if capacity growth lags demand growth, unmet need may persist even under zero copayment.
- 5 January 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Crisis to Recovery: Mental Health Service Demand in Alberta, Canada — A Policy Analysis with Illustrative Supply–Demand Modeling (2023–2024)
Background: COVID-19 coincided with increased mental health needs in Alberta, Canada, intensifying pre-existing access gaps and service strain. Alberta responded with publicly funded interventions spanning digital care, youth-focused services, and recovery-oriented programs. Objective: To evaluate Alberta’s system-level response to pandemic-related increases in mental health help-seeking/service uptake using a health economics and policy lens. Methods: We extracted empirically reported program delivery outputs from the 2023–2024 Alberta Mental Health and Addiction Annual Report. We used a simulation calibrated to reported trends to examine directional changes in help-seeking (demand), service capacity (supply), and the modeled equilibrium quantity under a zero-copayment design. Results: Empirically reported outputs indicate that delivery met or exceeded planned/funded milestones for CASA Mental Health, VODP, and tele-mental health, while recovery communities reflected phased implementation. In the illustrative simulation, the demand-implied volume increases from 60 to 87 services/month, but delivered volume is capacity-constrained at 78 services/month (implying ~9 services/month unmet demand), while a unit-cost proxy is held constant for visualization (not an observed market price or patient copayment).Conclusion: Alberta’s response illustrates how coordinated, publicly funded capacity expansion and access-oriented policies can support service delivery during system shocks; the model also highlights that if capacity growth lags demand growth, unmet need may persist even under zero copayment.
- Open Access
- 22 December 2025
- Published by MDPI AG in Preprints.org
Medicaid Expansion and Frequent Mental Distress in US Adults: Staggered Difference-in-Differences Evidence From BRFSS, 2011–2024
Background: The Affordable Care Act enabled states to expand Medicaid eligibility, potentially improving access to care and reducing psychological distress among low-income adults. Evidence on population-level mental health effects remains inconclusive, and conventional two-way fixed-effects difference-in-differences can be biased when adoption is staggered. Objective: To estimate the effect of Medicaid expansion on frequent mental distress (FMD) among non-elderly adults, with emphasis on low-income adults.Methods: We used Behavioral Risk Factor Surveillance System (BRFSS ) data from 2011 to 2024 and restricted the sample to adults aged 18–64 years. FMD was defined as reporting 14 or more days of poor mental health in the past 30 days. Medicaid expansion timing was assigned at the state level. For computational feasibility and transparent weighting, data were collapsed to the state-year level using BRFSS survey weights and screened for minimum unweighted cell size and effective sample size in the low-income panel. We estimated group-time average treatment effects using a staggered difference-in-differences framework implemented via csdid, clustering standard errors at the state level, and using pair-balanced observations when panels were unbalanced. We report pooled average effects and cohort-specific dynamic patterns. Results: In the low-income state-year panel (353 observations), Medicaid expansion was not associated with a statistically significant change in frequent mental distress (ATT −0.0125; 95% CI −0.0521 to 0.0271; p=0.54); estimates in the high-income and pooled panels were similarly small and not significant, while event-time estimates showed modest heterogeneity at selected leads/lags.Conclusions: Medicaid expansion was not associated with significant reductions in frequent mental distress at the population level during 2011–2024, though modest, time-varying effects may occur in specific expansion cohorts. Findings suggest that insurance expansion alone may be insufficient to meaningfully shift population psychological distress without complementary mental health and social support interventions.
- 22 December 2025
- Published by MDPI AG in Preprints.org
Open AccessMedicaid Expansion and Frequent Mental Distress in US Adults: Staggered Difference-in-Differences Evidence From BRFSS, 2011–2024
Background: The Affordable Care Act enabled states to expand Medicaid eligibility, potentially improving access to care and reducing psychological distress among low-income adults. Evidence on population-level mental health effects remains inconclusive, and conventional two-way fixed-effects difference-in-differences can be biased when adoption is staggered. Objective: To estimate the effect of Medicaid expansion on frequent mental distress (FMD) among non-elderly adults, with emphasis on low-income adults.Methods: We used Behavioral Risk Factor Surveillance System (BRFSS ) data from 2011 to 2024 and restricted the sample to adults aged 18–64 years. FMD was defined as reporting 14 or more days of poor mental health in the past 30 days. Medicaid expansion timing was assigned at the state level. For computational feasibility and transparent weighting, data were collapsed to the state-year level using BRFSS survey weights and screened for minimum unweighted cell size and effective sample size in the low-income panel. We estimated group-time average treatment effects using a staggered difference-in-differences framework implemented via csdid, clustering standard errors at the state level, and using pair-balanced observations when panels were unbalanced. We report pooled average effects and cohort-specific dynamic patterns. Results: In the low-income state-year panel (353 observations), Medicaid expansion was not associated with a statistically significant change in frequent mental distress (ATT −0.0125; 95% CI −0.0521 to 0.0271; p=0.54); estimates in the high-income and pooled panels were similarly small and not significant, while event-time estimates showed modest heterogeneity at selected leads/lags.Conclusions: Medicaid expansion was not associated with significant reductions in frequent mental distress at the population level during 2011–2024, though modest, time-varying effects may occur in specific expansion cohorts. Findings suggest that insurance expansion alone may be insufficient to meaningfully shift population psychological distress without complementary mental health and social support interventions.
- Open Access
- 2 December 2025
- Published by MDPI AG in Preprints.org
Balancing Cost, Innovation, and Access: A Comparative Institutional Analysis of Pharmaceutical Pricing Tools in High-Income Health Systems
Background: Soaring drug prices threaten affordability and equity in high-income health systems. This study examines how two families of reform tools, international reference pricing (including the U.S. Most Favored Nation–type proposals and Canada’s PMPRB comparators) and value-based payment approaches, perform across four core policy goals: cost containment, innovation, equity, and implementation feasibility.Methods: Guided by institutional and governance theories, we conducted a structured comparative policy analysis of the United States, Canada, and the United Kingdom using a four-dimensional trade-off matrix. We coded 37 documents (2007–2025), including policy guidance, legislation, and empirical evaluations, to rate each country–instrument pair (1–5) on cost, innovation incentives, equity of access, and feasibility, based on design features rather than realized outcomes.Results: The U.K.’s integrated model, combining NICE’s cost-effectiveness appraisals with the voluntary scheme for branded medicines (VPAG), shows the most consistent alignment across all four dimensions. Canada’s PMPRB-based system achieves strong cost control and broad baseline access but provides weaker, indirect innovation incentives and limited outcome-linked pricing. In the U.S., MFN-type proposals and pharmaceutical value-based contracts face legal challenges, fragmented payers, and limited infrastructure, resulting in low scores on equity and feasibility despite some innovation-supportive features.Conclusions: Neither international reference pricing nor value-based payment alone is sufficient to advance Universal Health Coverage goals. A hybrid approach, anchoring negotiations in international benchmarks while linking reimbursement to therapeutic value, appears more realistic for fragmented systems such as the U.S., but only if accompanied by investments in data, governance, and federal negotiating capacity. The trade-off matrix offers a repeatable framework for assessing pricing reforms and illustrates how institutional “fit,” rather than technical design alone, shapes policy success.
- 2 December 2025
- Published by MDPI AG in Preprints.org
Open AccessBalancing Cost, Innovation, and Access: A Comparative Institutional Analysis of Pharmaceutical Pricing Tools in High-Income Health Systems
Background: Soaring drug prices threaten affordability and equity in high-income health systems. This study examines how two families of reform tools, international reference pricing (including the U.S. Most Favored Nation–type proposals and Canada’s PMPRB comparators) and value-based payment approaches, perform across four core policy goals: cost containment, innovation, equity, and implementation feasibility.Methods: Guided by institutional and governance theories, we conducted a structured comparative policy analysis of the United States, Canada, and the United Kingdom using a four-dimensional trade-off matrix. We coded 37 documents (2007–2025), including policy guidance, legislation, and empirical evaluations, to rate each country–instrument pair (1–5) on cost, innovation incentives, equity of access, and feasibility, based on design features rather than realized outcomes.Results: The U.K.’s integrated model, combining NICE’s cost-effectiveness appraisals with the voluntary scheme for branded medicines (VPAG), shows the most consistent alignment across all four dimensions. Canada’s PMPRB-based system achieves strong cost control and broad baseline access but provides weaker, indirect innovation incentives and limited outcome-linked pricing. In the U.S., MFN-type proposals and pharmaceutical value-based contracts face legal challenges, fragmented payers, and limited infrastructure, resulting in low scores on equity and feasibility despite some innovation-supportive features.Conclusions: Neither international reference pricing nor value-based payment alone is sufficient to advance Universal Health Coverage goals. A hybrid approach, anchoring negotiations in international benchmarks while linking reimbursement to therapeutic value, appears more realistic for fragmented systems such as the U.S., but only if accompanied by investments in data, governance, and federal negotiating capacity. The trade-off matrix offers a repeatable framework for assessing pricing reforms and illustrates how institutional “fit,” rather than technical design alone, shapes policy success.